Repair Biotechnologies, backed by the VitaDAO community, received Orphan Drug Designation from the FDA for its cholesterol degradation therapy targeting HoFH, a rare genetic cause of early atherosclerosis. 🧬

From Twitter
Disclaimer: The content above is only the author's opinion which does not represent any position of Followin, and is not intended as, and shall not be understood or construed as, investment advice from Followin.
Like
Add to Favorites
Comments